Targeting of Immune Response After Pneumococcal Vaccination

Comparison of Immune Response in Pneumococcal Pneumonia and After Vaccination

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01402245

Acronym

PncHR

Enrollment

Registered

2011-07-26

Start date

2005-01-31

Completion date

2010-06-30

Last updated

2011-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumococcal Pneumonia

Keywords

pneumonia, pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine

Brief summary

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate vaccine (PCV)

Detailed description

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study compares the homing profiles of Pnc-specific plasmablasts in 15 patients with pneumonia and in 15 volunteers receiving Pnc polysaccharide vaccine (PPV) and 12 volunteers receiving Pnc conjugate vaccine (PCV)

Interventions

BIOLOGICALPneumococcal polysaccharide vaccine

Pneumococcal polysaccharide vaccine 0.5 ml i.m.

BIOLOGICALpneumococcal conjugate vaccine

pneumococcal conjugate vaccine 0.5 ml i.m.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 64 Years

Healthy volunteers

Yes

Inclusion criteria

* Males and females ≥ 18 and \<65 years of age. * General good health. * Written informed consent. * No previous vaccination against Pnc * No previous history of Pnc pneumonia * In pneumonia: Diagnosis of Pnc pneumonia within a week

Exclusion criteria

* \< 18 years, ≥65 of age. * In vaccinees: Acute disease at the time of enrollment. * Pregnancy or lactation. * Known immunodeficiency or immune suppressive treatment. * Any chronic illness that might interfere with the immune response * Alcohol or drug abuse * Any clinically significant history of known or suspected anaphylaxis or hypersensitivity (based on the investigator's judgement).

Design outcomes

Primary

Measure	Time frame	Description
Expression of homing receptors on circulating plasmablasts in Pnc pneumonia and after vaccination	Day 0 and Day 7-10	HR on circulating Pnc-specific plasmablasts are determined in patients with pneumonia on day 7-10, in vaccinees on days 0 and 7

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026